152626-91-0 Usage
Uses
Used in Pharmaceutical Industry:
6-Bromomethyl indazole is used as a key intermediate in the synthesis of various pharmaceutical compounds for [application reason]. Its unique chemical structure allows for the development of new drugs with potential therapeutic benefits.
Used in Organic Synthesis:
In the field of organic synthesis, 6-Bromomethyl indazole is utilized as a building block for the creation of complex organic molecules. Its reactivity and functional groups enable the formation of diverse chemical entities with specific properties and applications.
Used in Research and Development:
6-Bromomethyl indazole is employed as a research chemical in the development of new materials and chemicals. Its unique properties and reactivity make it a valuable tool for exploring novel chemical reactions and synthesizing innovative compounds.
It is important to handle 6-Bromomethyl indazole with care, as it can be harmful if swallowed, inhaled, or comes into contact with the skin. Proper safety measures should be taken during its use to ensure the well-being of individuals and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 152626-91-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,2,6,2 and 6 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 152626-91:
(8*1)+(7*5)+(6*2)+(5*6)+(4*2)+(3*6)+(2*9)+(1*1)=130
130 % 10 = 0
So 152626-91-0 is a valid CAS Registry Number.
152626-91-0Relevant articles and documents
Improved synthesis of 6-[(ethylthio)methyl]-1H-indazole
Sirven, Agns M.,Stefak, Roman,Rapenne, Gwnal
, p. 5 - 8 (2015)
In the improved synthesis of 6-[(ethylthio)methyl]-1H-indazole (5), the mesylate intermediate is replaced by the bromide derivative, which increases the overall yield (six steps) by a factor of 3.
Substituted hydrazinyl heteroaromatic inhibitors of thrombin
-
, (2008/06/13)
Compounds of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: as described herein.
